The House Ways and Means Committee hearing in late April signaled growing bipartisan frustration with a healthcare system that continues to produce rising costs without demonstrating better value, accountability or outcomes for employers, taxpayers and patient-consumers.

Healthcare delivery organizations should treat this moment as an opportunity to redesign how they compete by focusing on measurable outcomes, procedure-specific excellence and transparent evidence of both clinical and economic value.

The Hearing Wasn’t Only About Hospital Pricing

In Part 1 of this series, I wrote that the hearing signaled a broader shift in how policymakers are thinking about healthcare delivery. Congress is no longer satisfied with incremental fixes layered onto an outmoded business model.

Hospital executives raised legitimate concerns about labor shortages, inflation, administrative burden and reimbursement pressures. Those challenges are real.

But lawmakers kept returning to a larger question: after decades of consolidation and rising spending, why is there still so little evidence of measurable value tied to patient outcomes and total cost of care?